Stockpiling anti-viral drugs for a pandemic: The role of Manufacturer Reserve Programs

To promote stockpiling of anti-viral drugs by non-government organizations such as hospitals, drug manufacturers have introduced Manufacturer Reserve Programs which, for an annual fee, provide the right to buy in the event of a severe outbreak of influenza. We show that these programs enhance drug manufacturer profits but could either increase or decrease the amount of pre-pandemic stockpiling of anti-viral drugs.

MoreLess

Year of publication:	2010
Authors:	Harrington Jr., Joseph E. ; Hsu, Edbert B.
Published in:	Journal of Health Economics. - Elsevier, ISSN 0167-6296. - Vol. 29.2010, 3, p. 438-444
Publisher:	Elsevier
Subject:	Pricing Pharmaceutical products Pandemic

Online Resource

Check full text access |

More access options

Check Google Scholar

In libraries world-wide (WorldCat)

In German libraries (KVK)

subito order

I need help

More details

Type of publication:	Article
Source:	RePEc - Research Papers in Economics

Persistent link: https://www.econbiz.de/10008499144